Medpace (NASDAQ:MEDP) Stock Rating Upgraded by UBS Group

Medpace (NASDAQ:MEDP) was upgraded by equities researchers at UBS Group to a “hold” rating in a research note issued on Wednesday, Zacks reports.

A number of other equities research analysts have also weighed in on MEDP. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a report on Monday, September 14th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. BMO Capital Markets boosted their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Finally, Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $602.27.

Medpace Trading Up 0.3%

Shares of MEDP stock opened at $624.18 on Wednesday. The business’s 50-day moving average price is $600.14 and its 200-day moving average price is $519.59. Medpace has a 12 month low of $373.00 and a 12 month high of $677.90. The firm has a market capitalization of $17.42 billion, a price-to-earnings ratio of 36.59, a PEG ratio of 2.78 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, CEO August Troendle sold 2,410 shares of Medpace stock in a transaction on Monday, September 28th. The shares were sold at an average price of $620.07, for a total transaction of $1,494,368.70. Following the completion of the transaction, the chief executive officer owned 386,892 shares of the company’s stock, valued at $239,900,122.44. This trade represents a 0.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 287,473 shares of company stock worth $177,687,399 in the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Medpace

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Medpace in the second quarter valued at $1,323,047,000. Madison Asset Management LLC bought a new position in shares of Medpace during the 2nd quarter worth about $128,956,000. Bank of America Corp DE bought a new position in shares of Medpace during the 2nd quarter worth about $116,891,000. American Capital Management Inc. bought a new position in shares of Medpace during the 2nd quarter worth about $111,329,000. Finally, Franklin Resources Inc. grew its stake in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after buying an additional 183,645 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace to “Neutral” from “Sell” and raised its price target to $673 from $405. The sharp target increase suggests UBS believes the company’s earnings outlook and recent share-price momentum have improved, even though the firm does not yet recommend buying the stock. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace reported 17.2% second-quarter revenue growth. Its latest results also showed earnings per share of $4.25, above the $3.98 consensus estimate, while revenue of $707.33 million exceeded expectations of $689.51 million. Full-year 2026 earnings guidance remains $17.25-$17.95 per share, supporting the bullish fundamental case. Medpace reports second-quarter revenue growth
• Positive Sentiment: MEDP rose while the broader market declined. The relative strength indicates investors continued to favor the contract research organization after its earnings beat and revenue growth. Medpace rises as the market dips
• Neutral Sentiment: Analysts maintain an overall “Hold” consensus, with three Buy ratings and nine Holds and an average price target of $595.20. This target is below recent trading levels, suggesting valuation has already captured much of the expected improvement. Medpace receives average Hold rating
• Negative Sentiment: CEO August Troendle sold a combined 2,564 shares for roughly $1.59 million. The sales represent less than 1% of his holdings, so they are a modest negative signal rather than a major change in insider conviction. Medpace insider share sale

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.